The Cholesterol Test Market has demonstrated substantial growth, boasting a valuation of USD 6.35 billion in 2022. Projections indicate continued expansion, with expectations to reach USD 11.58 billion by 2030, marked by a robust compound annual growth rate (CAGR) of 7.8% throughout the forecast period spanning from 2023 to 2030. This upward trajectory is propelled by several factors, including the increasing prevalence of cardiovascular diseases, growing awareness about the importance of cholesterol management, and advancements in diagnostic technologies facilitating more accurate and convenient testing methods. As healthcare systems worldwide prioritize preventive care and population health management, the cholesterol test market is poised to play a pivotal role in early detection, risk assessment, and personalized treatment strategies, ultimately contributing to better patient outcomes and reduced healthcare burdens.